NEXGEL, Inc. (NXGL)
USD 4.23
(-10.19%)
USD 4.23
(-10.19%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.79 Million USD | 34.33% |
| 2022 | 2.08 Million USD | -51.15% |
| 2021 | 4.26 Million USD | 233.91% |
| 2020 | 1.27 Million USD | 39.26% |
| 2019 | 917 Thousand USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 2.99 Million USD | -2.51% |
| 2024 Q1 | 3.07 Million USD | 9.79% |
| 2023 Q4 | 2.79 Million USD | 17.81% |
| 2023 FY | 2.79 Million USD | 34.33% |
| 2023 Q3 | 2.37 Million USD | 1.89% |
| 2023 Q1 | 2.37 Million USD | 14.11% |
| 2023 Q2 | 2.33 Million USD | -1.94% |
| 2022 Q2 | 3.39 Million USD | 10.04% |
| 2022 Q3 | 2.12 Million USD | -37.53% |
| 2022 Q1 | 3.08 Million USD | -27.6% |
| 2022 FY | 2.08 Million USD | -51.15% |
| 2022 Q4 | 2.08 Million USD | -1.84% |
| 2021 Q4 | 4.26 Million USD | 20.08% |
| 2021 FY | 4.26 Million USD | 233.91% |
| 2021 Q3 | 3.55 Million USD | 21.03% |
| 2021 Q2 | 2.93 Million USD | 108.38% |
| 2021 Q1 | 1.4 Million USD | 10.26% |
| 2020 Q2 | 1.26 Million USD | 42.58% |
| 2020 Q1 | 890 Thousand USD | -2.94% |
| 2020 FY | 1.27 Million USD | 39.26% |
| 2020 Q4 | 1.27 Million USD | 2.57% |
| 2020 Q3 | 1.24 Million USD | -1.89% |
| 2019 Q4 | 917 Thousand USD | -2.76% |
| 2019 Q3 | 943 Thousand USD | -3.38% |
| 2019 FY | 917 Thousand USD | 0.0% |
| 2019 Q2 | 976 Thousand USD | -2.5% |
| 2019 Q1 | 1 Million USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 85.7 Million USD | 96.735% |
| AngioDynamics, Inc. | 5.91 Million USD | 52.689% |
| AtriCure, Inc. | 74.49 Million USD | 96.244% |
| Avinger, Inc. | 15.39 Million USD | 81.825% |
| Azenta, Inc. | 60.43 Million USD | 95.37% |
| BioLife Solutions, Inc. | 42.69 Million USD | 93.446% |
| The Cooper Companies, Inc. | 2.56 Billion USD | 99.891% |
| Daxor Corporation | 755.65 Thousand USD | -270.273% |
| Ekso Bionics Holdings, Inc. | 7.16 Million USD | 60.965% |
| Femasys Inc. | 6.7 Million USD | 58.244% |
| GlucoTrack, Inc. | 196 Thousand USD | -1327.551% |
| Harvard Bioscience, Inc. | 42.77 Million USD | 93.458% |
| Hologic, Inc. | 2.53 Billion USD | 99.89% |
| ICU Medical, Inc. | 1.7 Billion USD | 99.836% |
| Intuitive Surgical, Inc. | 89.8 Million USD | 96.884% |
| KORU Medical Systems, Inc. | 4.44 Million USD | 37.055% |
| LeMaitre Vascular, Inc. | 19.09 Million USD | 85.347% |
| Innovative Eyewear, Inc. | - USD | -Infinity% |
| Innovative Eyewear, Inc. | - USD | -Infinity% |
| Masimo Corporation | 970 Million USD | 99.712% |
| Microbot Medical Inc. | 231 Thousand USD | -1111.255% |
| Meihua International Medical Technologies Co., Ltd. | 7.33 Million USD | 61.834% |
| Merit Medical Systems, Inc. | 891.35 Million USD | 99.686% |
| Nephros, Inc. | 1.83 Million USD | -52.397% |
| NovoCure Limited | 596.24 Million USD | 99.531% |
| NEXGEL, Inc. | 2.79 Million USD | 0.0% |
| Singular Genomics Systems, Inc. | 75.28 Million USD | 96.284% |
| OraSure Technologies, Inc. | 13.5 Million USD | 79.28% |
| Pro-Dex, Inc. | 13.54 Million USD | 79.346% |
| Pulse Biosciences, Inc. | 9.14 Million USD | 69.401% |
| Predictive Oncology Inc. | 2.85 Million USD | 2.059% |
| Precision Optics Corporation, Inc. | 3.43 Million USD | 18.532% |
| QuidelOrtho Corporation | 2.61 Billion USD | 99.893% |
| Repligen Corporation | 711.8 Million USD | 99.607% |
| Sanara MedTech Inc. | 11.79 Million USD | 76.272% |
| STAAR Surgical Company | 35.83 Million USD | 92.192% |
| Sharps Technology, Inc. | - USD | -Infinity% |
| Utah Medical Products, Inc. | 342 Thousand USD | -718.129% |
| DENTSPLY SIRONA Inc. | 2.29 Billion USD | 99.878% |
| Jin Medical International Ltd. | 4.11 Million USD | 31.972% |